Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
September 07, 2023 10:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new...
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
September 05, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...
Beam Therapeutics to Participate in Upcoming September Investor Conferences
August 31, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
August 08, 2023 06:30 ET
|
Beam Therapeutics
BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of...
Beam Therapeutics to Participate in Upcoming May Investor Conferences
May 17, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 11, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
May 10, 2023 06:30 ET
|
Beam Therapeutics
Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites...
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023 07:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
March 21, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
March 15, 2023 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...